负载自体肿瘤抗原的DC-CIK细胞联合自体造血干细胞移植治疗难治性淋巴瘤的临床研究

Autologous tumor cell lysate-loaded dendritic cells and cytokine-induced killer cells in combination with autologous hematopoietic stem cell transplatation in the treatment of refractory lymphoma

目地观察负载自体肿瘤抗原的DC-CIK细胞联合自体造血干细胞移植治疗难治性淋巴瘤的疗效。方法选取难治性淋巴瘤35例,采用MAC预处理方案,用自体淋巴瘤抗原致敏DC-CIK细胞,于移植预处理后5—10d,将DC-CIK细胞回输给患者。结果35例难治性淋巴瘤中,29例完全缓解(82.86%),4例部分缓解(14.43%),移植过程中死亡2例(5.71%)(均死于严重混合性感染)。所有完全缓解和部分缓解病例均随访3—49个月:4名部分缓解患者分别于移植后3、6、10、13个月后病情进展死亡;完全缓解患者中有3人于移植后11、17、20个月再次复发死亡;现存活26例。结论负载自体肿瘤抗原的DC-CIK细胞联合自体造血干细胞移植治疗难治性淋巴瘤高于单纯自体外周血造血干细胞的疗效,且无明显毒副作用。

Objective To study the efficacy and side effect of autologous tumor cell lysate-loaded DC-CIK plus autologous hematopoietic stem cell transplantation in the treatment of refractory lymphoma. Methods Thirty-five cases of refractory lymphoma were recruited, lymphoma antigen-pulsed autologous DC-CIK cells were infused 5--10 days after the MAC conditioning regimen. Results Out of the 35 cases, complete remission was achieved in 29 （ 82. 8% ） , partial remission in 4 （ 14. 4% ）. Two patients died during transplantation due to severe mixed infections, with a transplant-related mortality rate of 5.7%. All cases of complete remission and partial remission were followed-up for 3--49 months, 4 cases with partial remission died 3,6,10,13 months after transplantation. Three cases with complete remission relapsed 11,17,20 months after transplantation, and the other 26 cases survived until now. Conclusion Autologous tumor eeU lysate-loaded DC-CIK combined with autologous hematopoietic stem cell transplantation in the treatment of refractory lymphoma is safe and effective.